The first cross-class fixed-dose combination, Atripla, was developed by Gilead and Bristol–Myers Squibb (BMS), and launched in 2006 in the United States. This once-daily pill containing an NNRTI ...

What is extraordinary about the ATRIPLA campaign cannot be defined in the language of the past. Like much of the breakthrough digital work today, the content and technological innovation of the ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target remains the same with $115.00. Discover outperforming ...